Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim in Down Syndrome
NCT05482334Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in Down syndrome, sponsored by University of Colorado Denver. Planned start Oct 2023; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT05482334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482334.